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The fragile X mental retardation protein FMRP regu-
lates translation of its bound mRNAs through incom-
pletely defined mechanisms. FMRP has been linked
to the microRNA pathway, and we show here that it
associates with the RNA helicase MOV10, also asso-
ciated with the microRNA pathway. FMRP associ-
ates with MOV10 directly and in an RNA-dependent
manner and facilitates MOV10’s association with
RNAs in brain and cells, suggesting a cooperative
interaction. We identified the RNAs recognized by
MOV10 using RNA immunoprecipitation and iCLIP.
Examination of the fate of MOV10 on RNAs revealed
a dual function for MOV10 in regulating translation: it
facilitates microRNA-mediated translation of some
RNAs, but it also increases expression of other
RNAs by preventing AGO2 function. The latter subset
was also bound by FMRP in close proximity to the
MOV10 binding site, suggesting that FMRP prevents
MOV10-mediated microRNA suppression. We have
identified a mechanism for FMRP-mediated transla-
tional regulation through its association with MOV10.
INTRODUCTION
Fragile X syndrome (FXS) is a disease of aberrant protein produc-
tion (Bolduc et al., 2008; Kelleher and Bear, 2008; Liu-Yesucevitz
et al., 2011). As a result, FXS patients are cognitively impaired
and have behavioral abnormalities that include autistic-like fea-
tures (Hagerman et al., 2009). The fragile X mental retardation
protein FMRP is absent in FXS, establishing that FMRP is
required for normal cognition. FMRP is an RNA binding protein
that binds 4% of brain mRNAs and regulates their expres-
sion—either enhancing or suppressing translation—by an un-
known mechanism (Brown et al., 2001; Miyashiro et al., 2003).
FMRP is implicated inmicroRNA (miRNA)-mediated translationalCell Resuppression (Caudy et al., 2002; Edbauer et al., 2010; Ishizuka
et al., 2002; Jin et al., 2004; Muddashetty et al., 2011), although
the molecular basis for its role is unknown.
In contrast, much is known about the molecular mechanism of
small RNA-mediated silencing (Wilson and Doudna, 2013). Upon
engaging a target mRNA, the nucleic acid binding cleft of Argo-
naute (AGO) opens to accommodate both the guide and target
strands (Pratt andMacRae, 2009). The guide strand, held in a he-
lical conformation by AGO, can increase the affinity of the target
up to300-fold by decreasing the entropic cost associated with
ordering the guide (Wilson and Doudna, 2013). Accordingly,
kinetic analyses show that human RNA-induced silencing com-
plex (RISC) (minimally the AGO-guide strand complex) increases
the ability of the guide to find and cleave its target RNA at a rate
ten times faster than the same small guide and target RNAs can
anneal in free solution (Ameres et al., 2007). Importantly, this
minimal RISC cannot unfold structured RNA, thus creating a
need for a protein to expose miRNA recognition elements
(MRE) located within highly structured RNAs.
MOV10 is a helicase that was initially identified in a screen of
mouse embryos intentionally infected with theMoloney leukemia
virus (MOV) (Jaenisch et al., 1981; Mooslehner et al., 1991). Like
FMRP, MOV10 has been implicated in miRNA-mediated transla-
tional suppression (Banerjee et al., 2009; Meister et al., 2005; Si-
evers et al., 2012). We show here that MOV10 has an effect on
the fate of its bound RNAs: usually facilitating translation sup-
pression, reflecting its role in the miRNA pathway; however, for
a subset of its RNAs, MOV10 increases their expression by
blocking AGO2 binding. These RNAs are also bound by FMRP.
We show that FMRP binding at or near the MOV10 binding site
blocks the usual role of MOV10 in the miRNA pathway.
RESULTS
FMRP Associates with MOV10
In addition to being implicated in themiRNA pathway, FMRP and
MOV10 are both expressed in brain and colocalize in dendritic
foci in cultured neurons, demonstrated by immunostaining
(Banerjee et al., 2009; Liu-Yesucevitz et al., 2011; Wulczynports 9, 1729–1741, December 11, 2014 ª2014 The Authors 1729
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Figure 1. FMRP Associates with MOV10 in Brain and Cell Lines
(A and B) Brain and HEK293 extracts were analyzed as in Kanai et al. (2004) and immunoblotted (ib) for FMRP andMOV10. Fractions with both FMRP andMOV10
were pooled and IP’ed for FMRP and MOV10 (right).
(C) myc-MOV10 was IP’ed, treated with RNase A, and ib for endogenous FMRP (Devys et al., 1993) and MOV10.
(D) FLAG-FMRPwas IP’ed from L-M(TK) cells (Ceman et al., 1999) in high EDTA to disrupt polysomes, treatedwith RNase A (+) or not () and 150mMor 300mM
NaCl, and ib for MOV10 or FLAG.
(E) Duplicate coimmunoprecipitation of 2 mM recombinant FMRP and MOV10 treated with RNaseA with irrelevant (Irr) or MOV10 antibody (MOV10) and ib for
FMRP or MOV10. Input: 5 ng of FMRP and 10 ng of MOV10.
(F) Polysome analysis of HEK293; 40S and 60S subunits, 80S ribosomes, and mRNAs with multiple ribosomes (polysomes) are indicated.
(G) EDTA treatment disrupts polysomes. The spike between fractions 7 and 8 is a technical artifact.
See also Figure S1.et al., 2007). To examine their physical association biochemi-
cally, we prepared an RNA sedimentation gradient on brain
and human embryonic kidney 293T (HEK293T) cells as
described previously (Kanai et al., 2004). Both FMRP and
MOV10 were present in fractions 7–15 in brain and 7–25 in
HEK293T cells (Figures 1A and 1B). To show that FMRP and
MOV10 are in the same complex in brain, we immunoprecipi-
tated (IP’ed) FMRP from brain lysate and found it associated
with MOV10 (Figure 1A, right). To demonstrate that FMRP and
MOV10 directly associate in fractions from the RNA sediment
gradient (versus being present individually in similarly sized pop-1730 Cell Reports 9, 1729–1741, December 11, 2014 ª2014 The Autulations), we pooled the MOV10- and FMRP-containing frac-
tions, IP’ed FMRP, and showed that MOV10 was associated
with FMRP (Figure 1B, right).
The interaction betweenMOV10 and FMRPwas characterized
by IP of myc-MOV10 in the presence or absence of RNase, and
we found that FMRP coimmunoprecipitated in a partially RNA-
dependent manner (Figure 1C). Further, anti-FLAG IPs of murine
fibroblast L-M(TK) cells stably expressing either empty FLAG
vector (VC) or FLAG-FMRP (Ceman et al., 1999) showed that
MOV10 associated with FMRP in a complex that was disrupted
in 300 mM NaCl and was partially disrupted by treatment withhors
RNase A (Figure 1D). These data suggest that association of
FMRP with MOV10 not only occurs in an RNA-dependent
manner but also has some protein-protein association. Accord-
ingly, purified recombinant FMRP incubated with similarly pre-
pared MOV10 in the presence of RNase A showed a direct asso-
ciation, demonstrating a protein-protein interaction between
FMRP and MOV10 (Figure 1E).
FMRP associates with translating ribosomes (polysomes)
(Feng et al., 1997; Khandjian et al., 1996). We hypothesized
that MOV10 interacts with FMRP to regulate translation. Exami-
nation of the distribution of FMRP and MOV10 on a sucrose
gradient showed both proteins in the same fractions as actively
translating polysomes (Figure 1F). Treatment with EDTA disrupts
polysomes and removes MOV10 and FMRP from the heavier
fractions, as described previously for FMRP (Feng et al., 1997;
Khandjian et al., 1996) (Figure 1G). Thus, FMRP associates
with MOV10 in an RNA- and protein-dependent manner and on
polysomes, suggesting a role in translational regulation.
Identification of Cellular RNAs Bound by Endogenous
MOV10
The RNAs associated with FMRP in brain and cell lines have
been extensively characterized (Ascano et al., 2012; Brown
et al., 2001; Darnell et al., 2011; Miyashiro et al., 2003). In addi-
tion, there are two studies of RNAs associated with ectopically
expressed MOV10 (Gregersen et al., 2014; Sievers et al.,
2012), which can result in altered intracellular localization (El
Messaoudi-Aubert et al., 2010). Because FMRP and MOV10
associate in a partially RNA-dependent manner (Figures 1C
and 1D), we used two independent approaches to identify
mRNAs associated with endogenous MOV10 (Figure S1). First,
we IP’ed MOV10 and prepared libraries from the associated
RNAs (RNA-IP) (Brown et al., 2001; Tenenbaum et al., 2000).
Second, we used the approach of individual-nucleotide-resolu-
tion UV crosslinking and immunoprecipitation (iCLIP) (Ko¨nig
et al., 2010, 2011), which allowed determination of the MOV10
binding regions on the identified RNAs. As a control for nonspe-
cific RNA binding, an irrelevant rabbit antibody (Winograd et al.,
2008) (ir) was used in parallel to the MOV10-specific IP
(Figure S1A).
RNAs that coimmunoprecipitated with MOV10 in the RNA-IP
were sequenced and compared to the transcriptome of
HEK293 cells. Approximately 80% of the reads were aligned
with sequences from exonic regions of the genome representing
18,831 protein-coding genes and 4,757 noncoding genes. We
used EdgeR to compare the RNA-IP samples with the total tran-
scriptome and identified 2,117 genes (2,039 protein coding
genes and 78 noncoding) that were significantly enriched
(Table S1).
For the iCLIP experiments, randombarcodes were used in two
independent library preparations and similar amounts of RNA
from each sample were sequenced. A total of 1.4 million (M)
mapped reads were obtained from both MOV10 iCLIP experi-
ments (698,430 and 686,898 mapped reads, respectively), here-
after referred to as C5 and C7 libraries (Figure S1B). In contrast,
only 0.2Mmapped reads were obtained from the combined irrel-
evant IPs (ir1 and ir2; Figure S1B). Among the genome-mapped
reads fromC5 andC7, 67%of the readsweremapped to regionsCell Rewithin genes, of which 33% aligned within 30 UTRs (Figure S1C).
Normalization of the reads (reads per kilobase of transcript per
million reads mapped) indicated that the 30 UTR had the highest
depth of coverage (Figure S1D).
In C5 and C7, 32,331 clusters were identified within 8,986
genes, with 15,475 of these clusters found in 30 UTRs. We fol-
lowed standard iCLIP protocols (Ko¨nig et al., 2010, 2011) to
determine the crosslink sites and obtain reads and their subse-
quent clusters, which were used to identify MOV10-associated
genes. Within the 32,331 clusters, 78% had multiple crosslink
sites and 5% had ten or more crosslink sites, indicating that
the MOV10 clusters were of high quality. Within these clusters,
62% of the crosslink sites were within one nucleotide of each
other and 88% were within 5 nt of each other (Figure S1E).
Only 1,687 clusters were observed in the irrelevant IP samples
and filtered for downstream analysis.
We compared the RNA-IP data to the iCLIP data (Tables S1
and S2, respectively) and found that most of the RNAs identified
in the iCLIP data (1,850 genes) were also significantly enriched
(2,117 genes) in the RNA-IP data (Figure S1F), indicating consis-
tency between the two experimental approaches. Although
some of the iCLIP targets were not enriched in the RNA-IP (Fig-
ure S1G, orange boxes), in general, the iCLIP targets were well
represented in the RNA-IP at different expression levels.
FMRP and MOV10 Bind a Subset of RNAs, and FMRP
Facilitates Association of MOV10 with Target mRNAs
Because we found MOV10 and FMRP associated in a partially
RNA-dependent manner in Figure 1, we identified the commonly
bound RNAs by comparing the CLIP lists of FMRP isolated from
HEK293 cells (Ascano et al., 2012) and brain polysomes (Darnell
et al., 2011) with the MOV10 iCLIP sites found at least once in
both C5 and C7 libraries. Using the permutation approach
described in Experimental Procedures, we found statistically
significant overlap in a number of shared target mRNAs
(Figure 2A).
The functional relationship of mRNAs bound by both FMRP
and MOV10 was examined using targets CALM3 and eEF2,
which were identified in both the RNA-IP and iCLIP and were
also present in the FMRP brain CLIP list (Darnell et al., 2011).
IP with an irrelevant antibody from wild-type (WT) and FMR1
knockout (KO) brains showed background levels of both RNAs
(Figure 2B). In contrast, IP of MOV10 from WT brains showed
significantly more eEF2 and CALM3 mRNA than that from
FMR1 KO brains (Figures 2B and 2C), suggesting that FMRP
facilitates the association of MOV10 with commonly bound
RNAs. As a control, we examined the amount of MOV10-associ-
atedGNB2L1 RNA, which is bound byMOV10 (Table S1 and S2),
but not FMRP, in brain (Darnell et al., 2011). MOV10-associated
GNB2L1 was the same in both the WT and FMRP KO mice (Fig-
ure 2C). The total level of all assessed RNAs was the same in
both WT and KO brains (Figure 2D).
To further explore the effect of FMRP on MOV10 association
with RNA, we IP’ed MOV10 from cells in which FMRP was
knocked down (KD) or overexpressed (OE). We found that
MOV10-associated RNAs decreased in the absence of FMRP
(Figure 2E), while those same mRNAs increased in association
with MOV10 when FMRP was OE (Figure 2F). Our resultsports 9, 1729–1741, December 11, 2014 ª2014 The Authors 1731
Figure 2. MOV10 Recognizes a Subset of RNAs Bound by FMRP
(A) Venn diagram of HEK293 MOV10 iCLIP targets, brain FMRP CLIP RNAs (Darnell et al., 2011), and FMRP isoform1 CLIP RNAs from transfected HEK293 cells
(Ascano et al., 2012). See Supplemental Experimental Procedures for details and statistical analysis and Table S4.
(B) RT-PCR of eEF2 and CALM3 RNAs synthesized with (+) or without () reverse transcription, irrelevant, or MOV10 IP from FMR1 KO and WT brains on a 2%
ethidium bromide gel.
(C) Quantitative PCR of MOV10-associated RNAs (eEF2, CALM3, and GNB2L1) IP’ed from WT and FMR1 KO brains (n = 3) and normalized to GAPDH.
(D) Quantitative PCR of RNAs from WT and FMR1 KO brains (n = 3).
(E) Quantitative PCR of MOV10 RNAs IP’ed from WT and FMR1 KD HEK293 cells (n = 3).
(F) Quantitative PCR of MOV10 RNAs IP’ed from WT and FMR1-OE HEK293 cells (n = 3).
Error bars represent SD, and p values were obtained by Student’s t test (*p < 0.05, **p < 0.01). See also Figure S2.suggest a cooperative interaction between FMRP and MOV10,
wherein FMRP binding to RNAs facilitates association with
MOV10. Total mRNA levels of target RNAs were unchanged by
FMRP KD or OE (Figure S2), agreeing with previous work (As-
cano et al., 2012).
MOV10 and AGO Bind Near Predicted MREs
and Recognize G-Rich Sequences
MOV10 has a physical and functional association with AGO
(Meister et al., 2005; Sievers et al., 2012). The high abundance
of MOV10 mapped sites in the 30 UTRs of target mRNAs is
consistent with a role for MOV10 in posttranslational regulation
through the miRNA pathway. Thus, we analyzed the relationship
between MOV10 binding sites and MREs. Based on the 6-mer
(2–7 nt at the 50 end of the miRNA) rules of miRNA binding, we
predicted the MREs for the top 100 highest expressed miRNAs
in HEK293 cells (Hafner et al., 2010) and calculated the distance1732 Cell Reports 9, 1729–1741, December 11, 2014 ª2014 The Autbetween the crosslink sites and its closest MREs. The crosslink
sites with the most reads within each cluster were selected for
analysis. Interestingly, 22.3% of the MOV10 crosslink sites
were located within the 5 nt flanking the MREs, 62% of the
MOV10 crosslink sites in the clusters were identified within
25 nt of their closest MREs, and 75.5% within 100 nt of the
closest MRE (Figure 3A). We also studied the distributions of
the AGO binding sites (Hafner et al., 2010) relative to the
MOV10 binding sites and found significant overlap among the
mRNAs targeted by both MOV10 and AGO, confirming the re-
sults of others (Sievers et al., 2012). A specific example is shown
with the RNA target GLE1 (Figure S3A). Despite differences be-
tween the samples and CLIP protocols, there were still 74%
(4,777 out of 6,436 AGO targets) of genes targeted by both
AGO and MOV10. Thus, MOV10 and AGO bind many of the
same mRNAs; however, we did not find significant precise over-
laps of their respective crosslink sites compared with what wehors
Figure 3. Characterization of MOV10 Bind-
ing Sites in the 30 UTR
(A and B) Fraction of MOV10 or AGO UV crosslink
sites plotted against distance in base pairs to
predicted MRE start site (Hafner et al., 2010).
(C) Relative distance between AGOCLIP sites and
MOV10 crosslink sites.
(D) Mean free energy plot of MOV10 30 UTR iCLIP
sites. DGfolding was calculated across 55 nt win-
dows ±275 nt from center of iCLIP site (black). %
GC content is plotted in red.
(E) RNA capture assay with GQ sc1 and sc1
mutant of in vitro synthesized FMRP and recom-
binant MOV10. Bottom: RNA input, ethidium gel.
See also Figure S3.have observed between their crosslink sites and MREs (Figures
3A and 3B). Only 918 of the AGO crosslink sites were within
25 bp from MOV10 target sites, although the crosslink sites
that did overlap increased with decreasing distance (Figure 3C).
In conclusion, MOV10 and AGO bind the same mRNAs in prox-
imity to MREs.
MOV10 Recognizes G-Rich and GQ-Containing Motifs
To identify the recognition motif of MOV10, we determined the
strandedness of the 30 UTR CLIP sites identified at least once
in both C5 and C7 libraries in Integrated Genomics Viewer
(IGV2.3), entered these sites into MEME (Bailey and Elkan,
1994), and identified three sequences that were collectively
found in 153 of the 454 genes analyzed (Figure S3B). Because
not all of the CLIP sites contained one of these three linearmotifs,
we analyzed the structural features of the 30 UTR CLIP sites by
calculating the mean free energy using a modified version of
ViennaRNA Package (Hofacker et al., 1994). The decrease inCell Reports 9, 1729–1741, DeDGfolding at the CLIP sites along with
a correlative increase in GC content
suggests that MOV10 recognizes and
binds GC-rich secondary structures
(Figure 3D).
The motifs recognized by FMRP have
been extensively characterized (Ascano
et al., 2012; Brown et al., 2001; Chen
et al., 2003; Darnell et al., 2001) and
include both G-rich sequences and G
quadruplexes (GQs) (Muddashetty et al.,
2011; Phan et al., 2011; Westmark and
Malter, 2007). GQs are stable nucleic
acid structures that can be substrates
for helicases, as is the case for the pri-
marily nuclear helicases G4R1/RHAU
and DHX9 (Chakraborty and Grosse,
2011; Creacy et al., 2008).
To examine the MOV10 iCLIP sites for
putative GQs, we used the GQ prediction
program QGRS Mapper (Kikin et al.,
2006; Menendez et al., 2012) and found
that 27.2% of the MOV10 30 UTR CLIP
sites contained predicted GQs—nearlytwice that predicted in a large-scale screen of 30 UTRs (Beaudoin
and Perreault, 2013). To ask directly whether MOV10 bound
GQs, we tested its ability to bind the RNA sc1, a model GQ
that binds FMRP with nanomolar affinity (Darnell et al., 2001).
Like FMRP, MOV10 specifically bound sc1 and was unable to
bind the nucleotide-substituted sc1 mutant, in which formation
of the GQ is disrupted (Figure 3E). Thus, both FMRP and
MOV10 are able to bind GQs.
MOV10 Regulates Expression through the 30 UTR and
Modulates AGO2 Function
Because MOV10 binds in close proximity to MREs and AGO
binding sites (Figure 3), we hypothesized that MOV10 functions
in the miRNA pathway. As a consequence of miRNA-mediated
translational suppression, it would be expected that a larger per-
centage of MOV10 target mRNAs would decrease (Baek et al.,
2008; Hendrickson et al., 2009; Guo et al., 2010; Lim et al.,
2005). Accordingly, KD of MOV10 should lead to an increase incember 11, 2014 ª2014 The Authors 1733
Figure 4. MOV10 Affects mRNA and Protein Levels of iCLIP Targets
(A) Venn diagram of significantly changed RNAs (FDR p < 0.05) in MOV10 KD (6057 RNAs) and OE experiments (7593 RNAs).
(B) iCLIP targets in MOV10 KD and OE were significantly changed compared to non-CLIP RNA (top, p = 0.0068, Chi-square test; bottom, p = 1.83 3 1026,
chi-square test).
(C) Heatmap of significantly changed MOV10 iCLIP RNAs in MOV10 KD, irrelevant siRNA (IR), and MOV10 OE created using weighted gene correlation network
analysis (WGCNA). Colored bars indicate discrete modules of RNAs. Individual experiments indicated at the bottom. Black brackets indicate anticorrelated
groups: top, MOV10 iCLIP targets increased upon KD and decreased upon OE (100 genes); bottom, MOV10 iCLIP targets decreased upon KD and increased
upon OE (39 genes).
(D) Distribution of RNAs inMOV10OE that did not change (blue), significantly decreased (green), or significantly increased (yellow) for total RNA (left), 30 UTRCLIP
targets (center), or intronic CLIP targets (right). See Supplemental Experimental Procedures for RNA-seq statistics.
(E) Distribution of RNAs inMOV10 KDwith no 30 UTRAGO2CLIP sites (left, 115 RNAs), overlappingMOV10 and AGO2CLIP sites in 30 UTR (center, 50 RNAs), and
nonoverlapping MOV10 and AGO2 CLIP sites in 30 UTR (left, 167 RNAs). Decreased: 21.7% versus 36% is significant; c2 = 2.9752, df = 1, p value = 0.04228
(legend continued on next page)
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mRNA levels. To examine the effect of MOV10 on total mRNA
levels, we treated cells with either MOV10 siRNAs for KD, irrele-
vant siRNAs as a control (IR), or overexpressed a MOV10 trans-
gene (OE) and evaluatedmRNA levels by RNA sequencing (RNA-
seq) (Table S3). We identified 14,679 RNAs in the total RNA pool
and found that 6057 RNAs changed significantly in the KD while
7,593 RNAs changed in the OE (Figure 4A). The changes in RNA
levels in both the KD and OE were significant (p < 0.05, false dis-
covery rate [FDR]) compared to the control treatment. A total of
3,313 genes significantly changed expression in both treatment
conditions. Of these, 1,216 RNAs changed in opposite directions
in the KDor OE: specifically, in the absence ofMOV10, 604 RNAs
increased while 612 decreased. In the OE, those same RNAs
changed in the opposite direction.
We compared the fate of the MOV10 iCLIP targets to the non-
CLIP targets. As expected, direct MOV10 binding had a signifi-
cant impact on the mRNA levels, with an overall increase in
mRNA expression in MOV10 KD and an overall decrease in
expression in MOV10 OE (Figure 4B, top, shift to right; bottom,
shift to left). MOV10 iCLIP targets changed significantly in the
KD (p = 0.0068) and the OE (p = 1.8333 1026) when compared
to the non-CLIP targets (Figure 4B; Table S3). The larger effect
observed in the OE experiment likely reflects OE of the MOV10
transgene (>30-fold; Table S3). Thus, RNAs that are directly
bound by MOV10 are more likely to have significantly altered
expression than the RNAs that are not CLIP targets under condi-
tions of MOV10 KD or OE.
We created a heatmap to visualize the fate of the MOV10 iCLIP
targets after MOV10 KD or OE. 312 genes had FDR p < 0.05 in KD
versus IR (mock treatment) (172 up/140 down) and 412 had FDR
p < 0.05 in OE versus IR (123 up/289 down). Combining these lists
yielded 541 genes in which 139 genes were anticorrelated: 100
genes increased in KD and decreased in OE (indicated toward
the topbyablackbar) aswouldbeexpected ifMOV10participates
in miRNA-mediated silencing. Importantly, there were also clus-
ters of RNAs that demonstrated the opposite expression pattern
(39 genes decreased in KD and increased in OE, bottom black
bar) (Figure 4C). These two expression patterns suggested that
MOV10 binding has two distinct fates: MOV10 binding decreases
the RNA levels of some iCLIP targets but increases the levels of
others. Because of the hypothesized role of MOV10 in the miRNA
pathway and the greater efficacy of MREs in the 30 UTR (Bartel,
2009; Eulalio et al., 2008; Hausser et al., 2013), we were particu-
larly interested in the fate of mRNAs in which MOV10 bound in
the 30 UTR. Examination of the effect of MOV10 OE on 30 UTR
CLIP targets revealed that47.2%weredecreased (Figure4D,cen-
ter) compared to the fate of non-CLIP RNAs (25%) and intronic
CLIP targets (30%) (Figure 4D), consistent with MOV10 having
a role in miRNA-mediated degradation.
We next analyzed the 30 UTR CLIP targets for the presence of
AGO2 CLIP sites (Xue et al., 2013), hypothesizing that MOV10
modulates miRNA-mediated translation suppression by either(one tailed). Increased: 10% versus 26.3%; c2 = 4.9842, df = 1, p value = 0.012
0.005881 (one tailed).
(F and G) irrelevant (Irrel) or MOV10 siRNA-treated HEK293 cells (MOV10 KD wa
independent experiments. Error bars were plotted using SD and p values using
See also Table S3 and Figure S4.
Cell Refacilitating or blocking AGO2 association. MOV10 and AGO2
bind in proximity to one another (Figure 3). We now examined
the fate of MOV10 iCLIP mRNAs upon MOV10 KD and observed
three categories of RNAs with 30 UTR MOV10 iCLIP sites: (1)
RNAs that contained no AGO2 CLIP sites in their 30UTR (Fig-
ure 4E, left), (2) RNAs with overlapping MOV10 and AGO2 CLIP
sites (Figure 4E, center), and (3) RNAs with MOV10 and AGO2
CLIP sites that did not overlap (Figure 4E, right). When there
was overlap between the MOV10 and AGO2 CLIP sites, the per-
centage of RNAs that decreased upon MOV10 KD was signifi-
cantly larger than the percentage of RNAs that decreased
when there were no AGO2 CLIP sites (36% compared to
21.7%, p = 0.042). This observation suggested a protective
role for MOV10 on those RNAs where the MOV10 and AGO2
CLIP sites overlapped such that loss of MOV10 led to decreased
RNAs. Accordingly, the percentage of RNAs that increased upon
MOV10 KD when the MOV10 and AGO2 sites overlapped was
significantly reduced compared to the percentages of increased
RNAs in the other two categories (10% compared to 26.3% and
29.6%, p < 0.05). Thus, when the MOV10 and AGO2 CLIP sites
overlap, MOV10 binding appeared to antagonize AGO2-medi-
ated transcript reduction.
To evaluate the fate of MOV10 on steady-state protein levels
encoded by individual CLIP targets, we examined the 30 UTR
MOV10 iCLIP targets whose RNAs are regulated by miRNAs in
HEK293 cells (Schmitter et al., 2006). MOV10 KD significantly
increased the expression of the endogenous proteins (Figure 4F),
aswould be expected ifMOV10 participated inmiRNA-mediated
suppression. In contrast, endogenous protein levels of MAZ and
WHSC1 were significantly decreased upon MOV10 KD (Fig-
ure 4G). Both proteins have overlapping MOV10 and AGO2
CLIP sites in their RNAs, suggesting that MOV10 blocks
miRNA-mediated suppression by inhibiting AGO2 binding—
either through steric hindrance or through an inability of
MOV10 to unwind and expose MREs. To both verify the effect
of MOV10 on the 30 UTR and test iCLIP targets for which anti-
bodies were not available, luciferase reporters of 30 UTRs were
examined (Figure S4A). Three other MOV10 targets with overlap-
ping MOV10 and AGO2 CLIP sites, namely eIF4B, HN1L, and
USP22, were also decreased in the absence of MOV10 (Fig-
ure S4A, right), supporting the idea that MOV10 binding blocks
AGO2 function when bound to the AGO2 site. However, realizing
that overlap of MOV10 and AGO2 on mRNA did not always lead
to increased mRNA or protein levels in the absence of MOV10
(Figure 4E, center), we hypothesized that another cofactor might
be playing a role in blocking translation suppression by AGO2.
FMRP Modulates MOV10’s Role as a Translational
Suppressor of Cobound mRNAs
Knowing that MOV10 binding is facilitated by FMRP on cobound
mRNAs (Figure 2), we wondered if there was an additional role
for FMRP in translation regulation. We examined binding79 (one tailed). Increased: 10% versus 29.6%; c2 = 6.3465, df = 1, p value =
s >80%); loading control, eIF5. Right: fold change in protein levels from three
Student’s t test (*p < 0.05, **p < 0.01).
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Figure 5. FMRP Modulates MOV10’s Role in Translational Regulation
(A) IGV screen capture of MAZ and LETM1 MOV10 iCLIP sites from C5 and C7 libraries, AGO2 CLIP sites (Xue et al., 2013), and FMRP CLIP sites (Ascano et al.,
2012).
(B) Overlay of MOV10 (blue), AGO (pink), and FMRP (green) crosslink sites plotted against distance in base pairs to predicted MRE start site. Random sites in
random genes were selected as a control (red).
(C) Effect of FMRP KD on luciferase expression of 30 UTRs of MOV10 iCLIP targets. Error bars represent SD, and p values were obtained by Student’s t test (*p <
0.05, **p < 0.01).
See also Figure S5.patterns within the 30 UTR (which often contained multiple FMRP
binding sites) that correlated with increased or decreasedmRNA
expression in the MOV10 KD. In the mRNAs in which expression
levels decreased upon MOV10 KD, we observed clear overlap in
AGO2, MOV10, and FMRP CLIP sites, of which MAZ, WHSC1,
USP22, HN1L, and eIF4B were included. We hypothesized that
FMRP binding at the site of MOV10/AGO2 overlap blocked
AGO2-mediated suppression. 30 UTRs from two representative
RNAs with opposite fates (and opposite FMRP binding profiles)
are shown in Figure 5A. LETM1 has no FMRPCLIP sites overlap-
ping the MOV10 and AGO2 CLIP sites and increases upon
MOV10 KD (Figures 4F and S4). In contrast, MOV10, FMRP,
and AGO2 CLIP sites overlap in MAZ, suggesting that proximal
binding of FMRP and MOV10 protects from AGO2 binding and
suppression (Figures 4G, 5A, and S4).1736 Cell Reports 9, 1729–1741, December 11, 2014 ª2014 The AutTo determine if FMRP has a role in regulating miRNA-medi-
ated translation, we analyzed the distance between predicted
MREs and the FMRP crosslink sites obtained from FMRP CLIP
data (Ascano et al., 2012). Similar to what we found for
MOV10, the majority of the FMRP 30 UTR CLIP sites (78%)
were within 25 nucleotides of a predicted MRE (Figure 5B, green
line). The strong correlation in the proximity of iCLIP sites to
known MRE sites for AGO, FMRP, and MOV10 suggests an
interactive role of these proteins in miRNA-mediated regulation
(Figure 5B).
To establish a role for FMRP in RISC function, we knocked
down FMRP and examined luciferase expression of the MAZ,
WHSC1, and USP22 30 UTR reporters (Figure 5C). In the FMRP
KD, we observed the same result as in the MOV10 KD, which
was a significant decrease in luciferase expression, suggestinghors
Figure 6. FMRP Modulates the Effect of MOV10 on AGO Function
(A) Effect of MOV10 KD onMAZ 30 UTR (WT) expression andmiR-328 site deletion (D-328) cotransfected with themiRNAs indicated. Error bars represent SD, and
p values were obtained by Student’s t test (*p < 0.05, **p < 0.01). See also Figure S6.
(B) Effect of MOV10 KD on AGO-associated RNAs (x axis) by quantitative PCR.
(C) Effect of FMRP KD on AGO-associated RNAs (x axis) by quantitative PCR.
(D and E) Quantitative PCR of additional AGO-associated RNAs in the presence or absence of MOV10 or FMRP. See also Figure S6.that FMRP protects thosemRNAs from suppression. In contrast,
LETM1, which has an FMRP CLIP site at the 30 end of the 30UTR
but does not overlap with the MOV10 iCLIP sites, showed an in-
crease in luciferase expression in the absence of FMRP, reflect-
ing typical miRNA-mediated translation suppression. The same
effect of FMRP KD was observed on the endogenous MAZ and
LETM1 proteins (Figure S5).
MOV10 Modulates Association with AGO
We used MAZ to demonstrate that MOV10 binding blocked
miRNA-mediated silencing by identifying candidate miRNAs us-
ing TargetScan that were tested for their ability to suppress MAZ
expression upon MOV10 KD (Figure S6A). miR-328 was identi-
fied as the primary miRNA associated with MOV10-mediated
suppression of theMAZ reporter (Figure 5A, red bar; Figure S6A).
We found that ectopic expression of miR-328 significantly
decreased MAZ 30 UTR reporter expression after MOV10 KD
(Figure 6A, compare the third column set to the first column
set), suggesting MOV10 blocks the effect of miR-328. To
demonstrate specificity, mutation of two nucleotides within theCell ReMRE of miR-328 in theMAZ 30 UTR reporter eliminated the effect
ofMOV10KD on expression, aswell as the ability of exogenously
introduced miR-328 to suppress the reporter (Figure 6A, third
column set, fourth column set, respectively). miR-150 was
used as a negative control. We conclude that MOV10 blocks
miR-328 mediated suppression of MAZ.
To determine whether MOV10 modulated AGO association
with the MAZ mRNA, we IP’ed AGO and quantified associated
MAZ RNA in the presence or absence of MOV10. Significantly
more MAZ mRNA associated with AGO in the MOV10 KD than
in the presence of MOV10 (Figure 6B), suggesting that MOV10
blocked AGO binding to MAZ. As a control, the CERS2 mRNA,
which is bound and regulated by AGO (Chi et al., 2009), but
not by MOV10 (Table S4), was bound equally well under both
conditions.
FMRP Affects AGO Binding to mRNA
Our hypothesis is that MOV10 generally facilitates AGO-medi-
ated suppression but its interaction with FMRP blocks suppres-
sion of a subset of mRNAs including MAZ. To test thisports 9, 1729–1741, December 11, 2014 ª2014 The Authors 1737
Figure 7. Model for MOV10-FMRP Associa-
tion in Translation Regulation
Top: fate of RNAs bound byMOV10. MOV10 binds
the 30 UTR-encoded G-rich structure to reveal
MREs for subsequent AGO2 association. Middle:
fate of RNAs bound by FMRP. FMRP binds RNAs
in the nucleus. Upon export, FMRP recruits
MOV10, which ultimately unwinds MREs for as-
sociation with AGO2.
Bottom: FMRP recruits MOV10 to RNAs; however,
binding of both FMRP and MOV10 in proximity
of MRE blocks association with AGO2. Red line
indicates MRE.hypothesis, we IP’ed AGO and determined whether FMRP
modulated AGO association with the MAZ mRNA by quantifying
AGO-associated RNAs in the presence or absence of FMRP.
AGO association with MAZ, was increased upon FMRP KD (Fig-
ure 6C), suggesting that like MOV10, FMRP blocks association
of AGO with MAZ.
MOV10 Can Modulate mRNA Expression through Its
Association with FMRP
Based on the results with MAZ, we examined mRNAs that con-
tained similar overlapping CLIP sites of FMRP,MOV10, and AGO
compared to mRNAs with nonoverlapped sites. We then deter-
mined whether AGO association with these target RNAs
changed in the presence or absence of MOV10 and FMRP. In
the MOV10 KD, we observed that WHSC1, which contained
overlapped binding sites andwas reduced uponMOV10KD (Fig-
ure 4G), showed an increase in AGO association, similar to what
we observed with MAZ (Figure 6D). In contrast, mRNA targets
that did not contain overlapped sites like LETM1 (Figure 5A)1738 Cell Reports 9, 1729–1741, December 11, 2014 ª2014 The Authorsand Phactr2 and had increased expres-
sion upon MOV10 KD (Figure 4F) resulted
in less AGO association upon MOV10 KD
(Figure 6D).
We previously showed that FMRP
facilitates MOV10 binding to cobound
mRNAs (Figure 2). Therefore, we ex-
pected to observe an overall decrease in
AGO-associated mRNAs in FMRP KD as
a result of reduced MOV10 recruitment,
which would have facilitated AGO associ-
ation by exposing MREs. Accordingly, in
the absence of FMRP, there was a
decrease in AGO-associated mRNAs in
which FMRP binding sites were not prox-
imal to MOV10 binding sites, as seen in
LETM1, PHACTR2, and MLLT6 (Fig-
ure 6E). However, AGO association with
MAZ, WHSC1, and USP22, all of which
contain FMRP sites coincident with
MOV10 binding sites, was increased
upon FMRP KD (Figure 6E), suggesting
that FMRP blocks association with AGO.
Taken together, this result indicates that
multiple FMRP sites within the RNA mayfacilitate MOV10 binding unless the AGO-FMRP-MOV10 sites
are coincident, in which case, FMRP and MOV10 block AGO
association.
In summary, we propose a model where MOV10 binding to
GC-rich structures facilitates RISC association by exposing
MREs in the mRNA. In the subset of mRNAs that are cobound
with FMRP, there are two distinct fates determined by where
they bind and interact in the 30 UTR. mRNAs that do not contain
an overlapped MOV10-FMRP site are translationally sup-
pressed, with FMRP facilitating MOV10 binding to the mRNA.
However, if FMRP is bound at or near the MOV10 binding site,
then MOV10 is unable to facilitate AGO interaction and the
mRNA is protected from AGO-mediated suppression (Figure 7).
This is a previously undescribed function for FMRP in the 30 UTR.
DISCUSSION
We hypothesize that FMRP binds the mRNAs first—perhaps in
the nucleus (Kim et al., 2009). Upon export to the cytoplasm,
FMRP may participate in granule formation through its low-
complexity sequence (Kato et al., 2012), recruiting MOV10 and
other proteins.
One hypothesis for FMRP facilitating MOV10 binding is that it
may stabilize areas of single-stranded mRNA, which allows
MOV10 to bind and initiate its helicase activity. Recent work by
Gregersen and colleagues showed that MOV10 binds single-
stranded RNA and translocates in a 50 to 30 direction within the
30 UTR (Gregersen et al., 2014). A second hypothesis, based
on the observation thatMOV10 and FMRP are found on polyribo-
somes and evidence that FMRP directly binds ribosomes (Chen
et al., 2014), is that the FMRP/MOV10 complex may translocate
with the ribosome to the translation termination site. In fact,
through the use of nontranslocating MOV10 mutants, Gregersen
and colleagues found that initial MOV10 binding takes place at
the accessible region at the beginning of the 30 UTR 21 nt
downstream of the terminating ribosome (Gregersen et al.,
2014). In both hypotheses, MOV10 unwinds GC-rich secondary
structure, allowing AGO2 to bind formerly inaccessible MREs,
consequently facilitating translational suppression. However, if
FMRP also binds at this site, AGO2 association is blocked. At
this point, FMRP may be competing with MOV10 for the same
G-rich sequence because both proteins bind GQs, or FMRP
may physically associate with MOV10 to prevent it from translo-
cating to unwind and reveal MREs. FMRP binds and stabilizes
GQs (Phan et al., 2011). Thus, it is possible that MOV10’s func-
tion as a helicase is hindered by FMRP’s ability to stabilize the
structure, therefore not allowing unwinding and consequently
access of AGO2 to the MRE.
In contrast to our work, Gregersen and colleagues observed
no enrichment of MOV10 PAR-CLIP reads around predicted
MREs in the 30 UTR.We suspect that this disparity reflects differ-
ences in how the data were interpreted and analyzed. We used
the actual MOV10 crosslink sites to infer a relationship with
MREs (as opposed to using read coverage, as they did). Using
actual MOV10 crosslink sites is amore reliablemethod to identify
high-quality binding sites (Hafner et al., 2010), and is not influ-
enced by transcript abundance (Uren et al., 2012). Using cross-
link sites also circumvents issues regarding PCR duplicates,
which can confound coverage density. Another significant differ-
ence between their study and ours is that they did not observe
FMRP association with MOV10. This important relationship
was probably not apparent in their data because of the NaCl
concentration used in their washes. We show that the associa-
tion of FMRP and MOV10 is preserved in 150 mM NaCl but
completely lost in 300 mM NaCl (Figure 1).
We provide evidence here of a role for FMRP in miRNA-
mediated regulation where in concert with MOV10, a subset
of mRNAs is protected from AGO2-mediated translation sup-
pression. We also show that FMRP binds in proximity to
MREs in the 30 UTR. KD of FMRP did not affect transcript levels
in our hands or in others (Ascano et al., 2012), which is at first
surprising in light of the genome-wide studies that have pro-
posed that miRNA-mediated repression mainly leads to
mRNA decay at steady state (Baek et al., 2008; Guo et al.,
2010; Hendrickson et al., 2009; Selbach et al., 2008). However,
as described in Be´thune et al. (2012), other studies show that
miRNA-mediated suppression can be rapidly reversed inCell Reresponse to different cellular cues (Bhattacharyya et al.,
2006; Muddashetty et al., 2011; Schratt et al., 2006). Reversible
silencing may be of critical importance in cells such as neu-
rons, where localized translation at synapses occurs in
response to stimulation, requiring that target mRNAs are
repressed translationally without major mRNA decay (Bhatta-
charyya et al., 2006; Muddashetty et al., 2011; Schratt et al.,
2006).
In demonstrating that MOV10 has a dual role in facilitating and
blocking AGO2 activity, this relationship is similar to the novel
function described for the polypyrimidine tract binding protein
PTB, which suppresses or enhances miRNA targeting by
competitive binding on target mRNAs or by altering local RNA
secondary structure (Xue et al., 2013). Like PTB, MOV10 joins
the growing list of RNA binding proteins that have been impli-
cated in modulating miRNA targeting (van Kouwenhove et al.,
2011).
In summary, we have identified a functional partner for FMRP
that modulates miRNA-mediated translation regulation by AGO,
giving insight into how FMRP regulates translation of a subset
of RNAs. In addition to its role as a translation suppressor
when it binds in the coding sequence (Darnell et al., 2011),
we have now identified a role for FMRP when it binds in the
30 UTR.
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